安帝君斯 AGEN 深 沪
已收盘 02-13 16:00:00 美东时间
2.92
+0.070
+2.46%
华盛通- 最 高3.005
- 今 开2.83
- 成交量 28.07万股
- 最 低 2.83
- 昨 收 2.85
- 总市值 1.06亿
- 52周最高 7.34
- 市盈率 静 --
- 换手率 0.78%
- 52周最低 1.38
- 委 比 84.23%
- 总股本 3614.17万
- 历史最高 202.5868
- 量 比 0.61
- 振 幅 6.14%
- 历史最低 1.38
- 每 手 1
- 风险率 1.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation
02-10 02:04
Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor
Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konfere
02-10 02:00
Agenus Expands Global Medical Affairs Infrastructure And Early-Access Support Capabilities In Response To Increasing Physician-Initiated Interest Regarding Authorized Access To BOT+BAL
Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid named-patient programs requestsAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced the
01-21 20:34
Agenus Expands Medical Affairs Infrastructure Amid Rising Demand for Botensilimab Access
Agenus Expands Medical Affairs Infrastructure Amid Rising Demand for Botensilimab Access Agenus Inc. has expanded its global Medical Affairs infrastructure to support growing physician interest in authorized access to its investigational immunotherapy combination, botensilimab plus balstilimab (BOT+
01-21 20:30
电话会总结 ｜ Agenus(AGEN)2024财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Agenus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至2024年第三季度末现金余额为4,480万美元，较2023年12月31日的7,610万美元大幅下降。季度结束后通过普通股销售额外筹集710万美元。 **营收表现：** 2024年第三季度营收2,500万美元，前九个月累计营收7,700万美元（包含非现金收入）。 **亏损情况：** 2024年第三季度净亏损6,700万美元，前九个月累计净亏损1.86亿美元，其中包含非现金运营费用分别为4,100万美元和1.12亿美元。 **现金流：** 2024年前九个
01-06 12:01
BRIEF-Agenus Appoints Dr. José Iglesias As Chief Medical Affairs Officer To Guide Global Medical Affairs And Early-Access Programs, Including France’S Aac
Agenus Inc AGEN.O: AGENUS APPOINTS DR. JOSÉ IGLESIAS AS CHIEF MEDICAL AFFAIRS OFFICER TO GUIDE GLOBAL MEDICAL AFFAIRS AND EARLY-ACCESS PROGRAMS, INCLUDING FRANCE’S AAC Source text: ID:nBwYGfkFa Furthe...
2025-11-18 21:41
Agenus reports Q3 results
Agenus press release (AGEN): Q3 GAAP EPS of $1.94. Revenue of $30.2M (+20.3% Y/Y). More on Agenus Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript Agenus Inc. (AGEN) Virtual Stakeholder Briefing...
2025-11-10 20:37
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consensus estimate of $1.98 by 2.02 percent. This is a 162.99 percent increase over losses of $(3.08) per share from the same
2025-11-10 20:32
Insights Ahead: Agenus's Quarterly Earnings
Agenus (NASDAQ:AGEN) is set to give its latest quarterly earnings report on Mon...
2025-11-08 04:05
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observedTumor types included CRC, sarcoma, ovarian, NSCLC,
2025-10-17 20:10
